News & Trends - Biotechnology

Australia’s Noxopharm advances NOXCOVID study

Health Industry Hub | January 14, 2021 |
[Total: 1    Average: 5/5]

Biotech News: Australian clinical stage drug development company, Noxopharm, announced that the latest formal review by the NOXCOVID-1 Safety Steering Committee has cleared it to advance to the fifth and final dosage cohort.

The NOXCOVID-1 phase 1 dose-escalation and dose-expansion study incorporates patients experiencing lung dysfunction associated with COVID-19.

Investigators moved to the 1800 mg dose after they reviewed the safety profile of Veyonda in 12 patients from Cohorts 3 and 4 (involving 800 and 1200 mg Veyonda respectively).

The Company will be reporting formally on efficacy in due course, with the overall objective being to use Veyonda to block the cytokine release syndrome (so-called ‘cytokine storm’) that leads to patients requiring intensive care, and is a primary cause of the multi-organ damage responsible for much of the long-term disability and death in COVID-19 patients.

Noxopharm CEO, Dr Graham Kelly, said “Patients we are treating are at the stage of COVID-19 disease generally associated with high rates of deteriorating lung function requiring intensive care. While early days, the progress of the trial is serving to boost our confidence that Veyonda is capable of meeting its primary objective of blocking the cytokine release syndrome causing that rapid deterioration, and doing so in a well-tolerated and minimally-intrusive way.”

The issues of drug safety and ease of administration look set to become major issues as the pandemic evolves. The emerging situations in the UK and parts of the U.S. are causing alarm, with hospitals reportedly being overwhelmed to the point of having insufficient ICU beds and staff to meet demand. The need for effective triage treatments able to be administered under minimal medical supervision in both developed and developing countries where lack of ICU facilities is even more concerning, looks set to grow exponentially. The Company sees Veyonda as having the properties to meet this need.

According to Dr Kelly “Noxopharm sees a commitment to the NOXCOVID trial as adding considerable commercial value to Veyonda, apart from obvious humanitarian reasons. With an estimated 11 million deaths each year from septic shock, the need to block cytokine release syndrome effectively and safely goes well beyond the current pandemic with its estimated approximately 2 million deaths to date.

“While Veyonda remains the Company’s current spearhead drug in the septic shock field with a potential major role to play in the pandemic, our subsidiary Pharmorage in collaboration with Hudson Institute of Medical Research and the Australian National University is underway in developing a drug purpose-built for septic shock across all situations,” she concluded.


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

News & Trends - Medical Technology

MedTech News - Sustained COVID-19 impact on cancer services and procedures

Sustained COVID-19 impact on cancer services and procedures

Health Industry Hub | January 15, 2021 |

MedTech News: Cancer Australia has released the latest in a series of reports analysing for the first time the significance […]

More


News & Trends - Medical Technology

MedTech News - Healthscope hospital leading in high-tech medical surgery

Healthscope hospital leading in high-tech medical surgery

Health Industry Hub | January 15, 2021 |

MedTech News: Healthscope’s Knox Private Hospital recently celebrated two key milestones, underscoring its reputation as a leading proponent of high-tech […]

More


News & Trends - Pharmaceuticals

Pharma News - Experts comment on AstraZeneca vaccine efficacy concerns

Experts comment on AstraZeneca vaccine efficacy concerns

Health Industry Hub | January 15, 2021 |

Pharma News: In light of the comments made regarding AstraZeneca’s COVID-19 vaccine efficacy by the Australian and New Zealand Society […]

More


Communication

Communication Pharma Biotech Medtech - Secrets of persuasion to influence anyone

Secrets of persuasion to influence anyone

Health Industry Hub | January 15, 2021 |

To understand the art of persuasion, you can turn to cognitive science for guidance in dealing with the unconscious mind. […]

More